|Articles|March 1, 2003

March 2003
Volume 9
Issue 3

Slow Response to Loss of Glycemic Control in Type 2 Diabetes Mellitus

Author(s)Jonathan B. Brown, PhD, MPP, Gregory A. Nichols, PhD

Download PDF: Slow Response to Loss of Glycemic Control in Type 2 Diabetes Mellitus

Articles in this issue

over 23 years ago

Article

How Do Minor Changes in the Definition of Blood Pressure Control Affect the Reported Success of Hypertension Treatment?

over 23 years ago

Article

Physician Attitudes Toward Strategies to Promote the Adoption of Medical Evidence Into Clinical Practice

over 23 years ago

Article

Patient Reports of Coverage Denial: Association With Ratings of Health Plan Quality and Trust in Physician

over 23 years ago

Article

Restoring Trust to Managed Care, Part 2: A Focus on Physicians

over 23 years ago

Article

Review of the Newer Antiepileptic Drugs

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

The Timing and Characteristics of Supplemental Indications for Medicines

ByYingying Zhu, PhD,Claire H. Brennan, BA,Haijun Tian, PhD,Josephine N. Tran, PharmD, MS,Peter J. Neumann, ScD,James D. Chambers, PhD,Pei-Jung Lin, PhD,Meng Li, PhD

July 6th 2026

Slow Response to Loss of Glycemic Control in Type 2 Diabetes Mellitus

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The Future of Myeloma Treatment: Ajai Chari, MD

COVID-19 Medicare Spending Falls After Acute Infection

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Slow Response to Loss of Glycemic Control in Type 2 Diabetes Mellitus

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The Future of Myeloma Treatment: Ajai Chari, MD

COVID-19 Medicare Spending Falls After Acute Infection